• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Nycomed's Omniscan approved in Japan

Article

Hafslund Nycomed's Omniscan MRI contrast agent has been certifiedfor marketing in Japan, the Oslo, Norway, company reported thismonth. Nycomed said that Omniscan will be launched by DaiichiPharmaceutical, Nycomed's Japanese licensee, as soon as

Hafslund Nycomed's Omniscan MRI contrast agent has been certified

for marketing in Japan, the Oslo, Norway, company reported this

month. Nycomed said that Omniscan will be launched by Daiichi

Pharmaceutical, Nycomed's Japanese licensee, as soon as final

price approval is granted by Japanese authorities. Nycomed added

that it has submitted an application for marketing approval in

Japan for Visipaque, its third-generation x-ray contrast agent.

Recent Videos
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 2
Related Content
© 2025 MJH Life Sciences

All rights reserved.